Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New diabetes drink shows promise in nutrition study

NCT ID NCT06632002

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 21, 2026 · Updated 2 times

Summary

This study compares a new diabetes-specific nutritional formula to an existing one in 103 adults with type 1 diabetes, type 2 diabetes, or prediabetes who are at risk for malnutrition. The goal is to see if the new formula is as good as the current one at improving nutrition, measured by blood protein levels and malnutrition risk scores. Participants receive the drink as part of their daily diet for 90 days.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

103 people

The number who actually took part.

Started

Jan 2025

Finished

May 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Participants are eligible to be included in the study only if all of the following criteria apply: 1. Has any of the following types of diabetes: 1. Type 1 diabetes 2. Type 2 diabetes 3. Prediabetes 2. Has MNA-SF score of ≤ 11 3. Serum albumin less than 4.0 g/dL 4. Energy or protein intake less than recommended 5. BMI less than 30.0 kg/m2 6. Either a male or a non-pregnant, non-lactating female, at least 6 weeks postpartum prior to the study 7. Female of childbearing potential to use an effective method of birth control 8. Chronic medication type and dose to be constant and maintained throughout the study 9. Willing to follow the protocol throughout the study 10. At least a two-week washout period between the completion of a previous research study and start in current study 11. Willing to refrain from taking non-study diabetes-specific formula over the course of the study. Exclusion Criteria Participants are excluded from the study if any of the following criteria apply: 1. Has a screening HbA1c level less than 5.0% or ≥ 10% 2. Has a current infection, inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or received antibiotics in the last 3 weeks 3. Has active malignancy within the last 5 years 4. Has significant cardiovascular event within 6 months prior to the study or history of congestive heart failure 5. Has end-stage organ failure or is post-organ transplant 6. Has current or history of renal disease or on dialysis or severe gastroparesis 7. Has current hepatic disease 8. Has a recent acute infection, physiologic stress or trauma within 1 month prior to the study 9. Has had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery that can interfere with consumption or digestion or absorption of study product 10. Has a chronic, contagious, infectious disease 11. Has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study procedures 12. Taking any herbals, dietary supplements or medications during the past 4 weeks prior to the study 13. Using diabetes-specific formula(s) or oral nutritional supplement formula(s) in more than one eating occasion per week within the past 3 months 14. Has clotting or bleeding disorders 15. Has blood or blood-related diseases 16. Has received blood transfusion within the last 3 weeks 17. Has allergy or intolerance to the study product 18. Anticipated poor compliance to the study as assessed by the Investigator 19. Participates in another study that has not been approved as a concomitant study by Abbott Nutrition

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Chung Shan Medical University

    Taichung, 40201, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.